Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has reported financial results for the first half of 2026, highlighting a 23% increase in revenue and significant progress in its contract development and manufacturing organization (CDMO) business. The company recorded revenue of $949,000 for the six-month period, up from $773,000 in the prior-year period, driven by growing demand for its manufacturing services. As of Aug. 16, 2026, committed customer orders reached approximately $3.1 million, including about $2.1 million already invoiced, reflecting a robust pipeline of business.
The company is advancing an expanded clinical manufacturing and chemistry, manufacturing and controls (CMC) program for a U.S.-based biopharmaceutical company. This initiative, which supports an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development, has already generated approximately $650,000 in cash payments and advances. While a definitive agreement is still under negotiation, substantive activities are underway, underscoring the strategic importance of this collaboration. Scinai continues to pursue approximately $5 million in CDMO revenue for 2026, positioning its manufacturing arm as a key growth driver.
Financially, the company reported an operating loss of approximately $4.6 million for the first half, compared with a loss of $3.8 million in the same period last year. However, net income swung to a positive $1.6 million, versus a net loss of $4.1 million in the prior-year period, primarily due to a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel. As of June 30, 2026, cash, cash equivalents, and restricted cash totaled approximately $2.9 million, providing a foundation for ongoing operations.
Beyond its CDMO activities, Scinai continues to advance its therapeutic pipeline, including PC111 and its NanoAbs programs. The company is scheduled to host an investor webinar on Aug. 26, 2026, to discuss recent developments, financial performance, and upcoming milestones. This event offers stakeholders an opportunity to gain deeper insight into the company's strategic direction.
The implications of these results are significant for Scinai's dual business model. The growth in CDMO revenue and the expansion of the U.S. clinical manufacturing program demonstrate the company's ability to leverage its facilities in Jerusalem and Yavne, Israel, to attract international clients. This diversification helps mitigate the risks inherent in drug development while providing a steady revenue stream. The advancement of the CMC program toward an IND submission and Phase III trials for a U.S. partner could lead to long-term manufacturing contracts, further solidifying Scinai's position in the biopharmaceutical supply chain.
For investors, the positive net income, driven by the bargain purchase gain, provides short-term financial relief, but the sustained growth of the CDMO segment will be crucial for long-term stability. The company's pursuit of $5 million in CDMO revenue for 2026, coupled with the ongoing therapeutic development, positions Scinai to potentially create value across both its service and product lines. As the biopharmaceutical industry increasingly outsources manufacturing and development, Scinai's integrated capabilities could make it a preferred partner for companies seeking to advance their pipelines efficiently.
